This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2010 Feb:36 Suppl 1:S15-6.

doi: 10.1016/S0305-7372(10)70003-7.

Panitumumab - an effective long-term treatment for patients with metastatic colorectal cancer and wild-type KRAS status

Elena Elez¹, Maria Alsina, Josep Tabernero

Affiliations

PMID: 20189055
DOI: 10.1016/S0305-7372(10)70003-7

Review

Panitumumab - an effective long-term treatment for patients with metastatic colorectal cancer and wild-type KRAS status

Elena Elez et al. Cancer Treat Rev. 2010 Feb.

. 2010 Feb:36 Suppl 1:S15-6.

doi: 10.1016/S0305-7372(10)70003-7.

Authors

Elena Elez¹, Maria Alsina, Josep Tabernero

Affiliation

¹ Medical Oncology Department, Vall d'Hebron University Hospital, P. Vall d'Hebron, Barcelona, Spain.

PMID: 20189055
DOI: 10.1016/S0305-7372(10)70003-7

No abstract available

PubMed Disclaimer

Comment on

Successful long-term management of a patient with late-stage metastatic colorectal cancer treated with panitumumab.
Seront E, Marot L, Coche E, Gala JL, Sempoux C, Humblet Y. Seront E, et al. Cancer Treat Rev. 2010 Feb;36 Suppl 1:S11-4. doi: 10.1016/S0305-7372(10)70002-5. Cancer Treat Rev. 2010. PMID: 20189054

Similar articles

Sweeping KRAS generalizations: are we depriving patients of an effective treatment? A novel KRAS mutation and dramatic response to panitumumab in a patient with metastatic colorectal cancer.
Zikria J, Krishnamoorthy S, Kaley K, Saif MW. Zikria J, et al. Int J Colorectal Dis. 2011 Oct;26(10):1353-4. doi: 10.1007/s00384-010-1117-0. Epub 2011 Jan 13. Int J Colorectal Dis. 2011. PMID: 21229361 No abstract available.
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A. Di Nicolantonio F, et al. J Clin Oncol. 2008 Dec 10;26(35):5705-12. doi: 10.1200/JCO.2008.18.0786. Epub 2008 Nov 10. J Clin Oncol. 2008. PMID: 19001320
Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab?
Garassino MC, Farina G, Rossi A, Martelli O, Torri V. Garassino MC, et al. J Clin Oncol. 2008 May 20;26(15):2600; author reply 2601-2. doi: 10.1200/JCO.2008.16.8195. J Clin Oncol. 2008. PMID: 18487581 No abstract available.
Panitumumab in metastatic colorectal cancer.
Hocking CM, Townsend AR, Price TJ. Hocking CM, et al. Expert Rev Anticancer Ther. 2013 Jul;13(7):781-93. doi: 10.1586/14737140.2013.811064. Epub 2013 Jun 26. Expert Rev Anticancer Ther. 2013. PMID: 23802848 Review.
Panitumumab: in metastatic colorectal cancer with wild-type KRAS.
Weber J, McCormack PL. Weber J, et al. BioDrugs. 2008;22(6):403-11. doi: 10.2165/0063030-200822060-00006. BioDrugs. 2008. PMID: 18998757 Review.

See all similar articles

Cited by

Management of liver metastases from colorectal cancer.
Katayose Y, Unno M. Katayose Y, et al. Clin J Gastroenterol. 2010 Jun;3(3):128-35. doi: 10.1007/s12328-010-0155-z. Epub 2010 May 13. Clin J Gastroenterol. 2010. PMID: 26190118
Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers.
Khelwatty SA, Essapen S, Seddon AM, Fan Z, Modjtahedi H. Khelwatty SA, et al. Br J Cancer. 2015 Sep 29;113(7):1010-9. doi: 10.1038/bjc.2015.319. Epub 2015 Sep 15. Br J Cancer. 2015. PMID: 26372697 Free PMC article.
Clinical outcome of panitumumab for metastatic colorectal cancer with wild-type KRAS status: a meta-analysis of randomized clinical trials.
Ibrahim EM, Abouelkhair KM. Ibrahim EM, et al. Med Oncol. 2011 Dec;28 Suppl 1:S310-7. doi: 10.1007/s12032-010-9760-4. Epub 2011 Jan 9. Med Oncol. 2011. PMID: 21221853
Personalized therapy for pancreatic cancer: Myth or reality in 2010?
Huang TC, Kar S, Javle M. Huang TC, et al. J Gastrointest Oncol. 2010 Sep;1(1):24-33. doi: 10.3978/j.issn.2078-6891.2010.009. J Gastrointest Oncol. 2010. PMID: 22811802 Free PMC article. No abstract available.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal